Document Detail


High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
MedLine Citation:
PMID:  11325081     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We recently demonstrated that spironolactone may have beneficial effects on left ventricular hypertrophy in selected patients with essential hypertension undergoing treatment with an angiotensin-converting enzyme (ACE) inhibitor. To clarify the possible mechanisms by which spironolactone improves cardiac hypertrophy, we investigated the change in serum procollagen type III amino-terminal peptide (PIIINP) in 11 patients with essential hypertension treated with spironolactone and an ACE inhibitor for 24 weeks. Both blood pressure and serum PIIINP levels were significantly decreased by treatment. There was a statistical significant correlation between the changes in LVMI and those in PIIINP. The reduction in PIIINP was significant in patients whose initial serum PIIINP levels were above the normal range. Before treatment, there were no statistically significant correlations between serum PIIINP levels and either LVMI, blood pressure, or plasma aldosterone concentration. Essential hypertensive patients matched in terms of duration of therapy, blood pressure and LVMI and treated with an ACE inhibitor alone showed no change in serum PIIINP levels. In conclusion, the results of the present study demonstrate that patients with essential hypertension and high serum levels of PIIINP are particularly responsive to MR blockade in terms of left ventricular hypertrophy. Moreover, these results suggest that spironolactone limits cardiac collagen turnover in such patients. Larger studies may provide definitive evidence for the involvement of aldosterone in left ventricular hypertrophy in patients with abnormally high PIIINP levels.
Authors:
A Sato; H Takane; T Saruta
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  24     ISSN:  0916-9636     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-04-27     Completed Date:  2001-08-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  99-104     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Mito Red Cross Hospital, Ibaraki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
Diuretics / administration & dosage*
Female
Humans
Hypertension / blood,  drug therapy*
Hypertrophy, Left Ventricular / blood,  drug therapy*
Indoles / administration & dosage*
Male
Middle Aged
Peptide Fragments / blood*
Procollagen / blood*
Spironolactone / administration & dosage*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Diuretics; 0/Indoles; 0/Peptide Fragments; 0/Procollagen; 0/procollagen Type III-N-terminal peptide; 52-01-7/Spironolactone; 87679-37-6/trandolapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Family history of hypertension and blood pressure in a screened cohort.
Next Document:  Laparoscopic orthotopic ileal neobladder.